Alyftrek (vanzacaftor / tezacaftor / deutivacaftor)

A once-daily triple combination tablet that improves on Trikafta's twice-daily regimen. Approved for the same broad range of CFTR mutations with a simplified dosing schedule.

Alyftrek is a next-generation version of triple-combination CF therapy, with two correctors (vanzacaftor and tezacaftor) that help the CFTR protein fold and reach the cell surface, and one potentiator (deutivacaftor) that helps it stay open. Taking it just once daily instead of twice daily helps patients stick with their treatment.

Alyftrek has a boxed warning for liver injury and liver failure. Serious and sometimes fatal liver injury has been reported with Trikafta, which has the same or similar ingredients. Your doctor should check liver blood tests before you start, every month for the first 6 months, every 3 months for the next 12 months, and at least once a year after that. It should not be used in people with severe liver impairment and is not recommended for people with moderate liver impairment. Serious allergic reactions, including anaphylaxis, have been reported with related CF medicines that contain elexacaftor, tezacaftor, or ivacaftor. Stop taking Alyftrek and get emergency help if signs of a serious allergic reaction appear. The most common side effects include cough, cold symptoms, upper respiratory infection, headache, sore throat, flu, tiredness, rash, and raised liver enzymes. The label also warns about raised pressure in the skull (call your doctor about an unusual headache or vision changes), anxiety, depression, sleep problems or suicidal thoughts, and cataracts in children, who need eye exams. Avoid food or drink with grapefruit. The label also warns that some other medicines can make Alyftrek work less well or raise the risk of side effects, so tell your doctor about every medicine you take, and that people who stopped Trikafta or a similar CF medicine because of side effects need careful monitoring if they start Alyftrek. Tell your doctor right away about yellowing of skin or eyes, dark urine, or unusual tiredness.

Alyftrek is taken once daily by mouth as a tablet with a fat-containing meal. This once-daily dosing is simpler than Trikafta's twice-daily schedule. Approved for children ages 6 and older with responsive CFTR mutations.

Yes, Vanzacaftor / Tezacaftor / Deutivacaftor (Alyftrek) is FDA approved (2024) for the treatment of Cystic Fibrosis.

The primary advantage is once-daily dosing. Trikafta requires 2 doses per day (morning and evening), while Alyftrek is taken as a single tablet once daily with a fat-containing meal. In clinical trials (SKYLINE), Alyftrek also demonstrated superior reduction in sweat chloride levels compared to Trikafta, suggesting potentially stronger correction of the CFTR protein defect, though lung function improvements were comparable.

Yes, switching from Trikafta to Alyftrek is an option patients can discuss with their CF care team. Both drugs cover a similar range of CFTR mutations. The decision to switch typically depends on factors like dosing convenience, how well you tolerate your current regimen, and your specific clinical response. Your doctor can guide the transition timing and monitoring.

Deutivacaftor is a deuterium-modified version of ivacaftor. Deuterium is a naturally occurring, heavier form of hydrogen that, when swapped into specific positions on the ivacaftor molecule, slows the body's metabolism of the drug. This means deutivacaftor stays active in the body longer than ivacaftor, which is one reason Alyftrek can be dosed once daily instead of twice daily like Trikafta.

The 2 SKYLINE Phase 3 trials enrolled 971 CF patients age 12 and older and compared Alyftrek head-to-head against Trikafta. Alyftrek met its primary endpoint of non-inferiority in lung function improvement (ppFEV1) and showed superiority in reducing sweat chloride levels. Some patients on Alyftrek achieved sweat chloride levels in the normal, non-CF range, suggesting near-complete correction of CFTR function. The safety profile was similar to Trikafta.

Alyftrek is approved for patients age 6 and older with at least one CFTR variant that responds to it or that makes CFTR protein (the FDA broadened this wording in March 2026). Younger children (under 6) are not yet eligible, though pediatric studies may expand the age range in the future. Trikafta is currently approved down to age 2, so younger children would remain on Trikafta or Kalydeco depending on their mutation and age.

Both are specialty-priced branded medications from Vertex Pharmaceuticals with no generic alternatives. Pricing varies by insurance plan, and Vertex offers the same GPS (Guidance & Patient Support) program for both drugs, including copay assistance for commercially insured patients. Your insurance formulary and Vertex's support team can help clarify your specific out-of-pocket costs.